tradingkey.logo

enVVeno Medical Corp

NVNO
查看詳細走勢圖
0.355USD
+0.013+3.74%
收盤 12/24, 13:00美東報價延遲15分鐘
7.17M總市值
虧損本益比TTM

enVVeno Medical Corp

0.355
+0.013+3.74%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.74%

5天

+2.93%

1月

+2.75%

6月

-91.47%

今年開始到現在

-88.25%

1年

-87.42%

查看詳細走勢圖

TradingKey enVVeno Medical Corp股票評分

單位: USD 更新時間: 2025-12-24

操作建議

enVVeno Medical Corp當前公司基本面數據相對謹慎,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名211/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價12.50。中期看,股價處於下降通道。近一個月,市場表現一般,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。

enVVeno Medical Corp評分

相關信息

行業排名
211 / 404
全市場排名
379 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
持有
評級
12.500
目標均價
+1517.29%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

enVVeno Medical Corp亮點

亮點風險
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
估值高估
公司最新PE估值-0.33,處於3年歷史高位
機構減倉
最新機構持股5.69M股,環比減少10.50%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉29.20K股
活躍度增加
近期活躍度增加,過去20天平均換手率8.32

enVVeno Medical Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

enVVeno Medical Corp簡介

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
公司代碼NVNO
公司enVVeno Medical Corp
CEOBerman (Robert A)
網址https://envveno.com/

常見問題

enVVeno Medical Corp(NVNO)的當前股價是多少?

enVVeno Medical Corp(NVNO)的當前股價是 0.355。

enVVeno Medical Corp 的股票代碼是什麼?

enVVeno Medical Corp的股票代碼是NVNO。

enVVeno Medical Corp股票的52週最高點是多少?

enVVeno Medical Corp股票的52週最高點是5.620。

enVVeno Medical Corp股票的52週最低點是多少?

enVVeno Medical Corp股票的52週最低點是0.301。

enVVeno Medical Corp的市值是多少?

enVVeno Medical Corp的市值是7.17M。

enVVeno Medical Corp的淨利潤是多少?

enVVeno Medical Corp的淨利潤為-21.82M。

現在enVVeno Medical Corp(NVNO)的股票是買入、持有還是賣出?

根據分析師評級,enVVeno Medical Corp(NVNO)的總體評級為持有,目標價格為12.500。

enVVeno Medical Corp(NVNO)股票的每股收益(EPS TTM)是多少

enVVeno Medical Corp(NVNO)股票的每股收益(EPS TTM)是-1.078。
KeyAI